Literature DB >> 7858527

Generation of self HLA-DR-specific CD3+CD4-CD8+ cytotoxic T cells in chronic graft-versus-host disease.

M Yamamoto1, K Sugihara, F Ohtsuki, Y Tsujino, A Tanaka, T Kamiya, H Wada, A Kanamaru, H Hara, A Yano.   

Abstract

To analyze the mechanism of chronic graft-versus-host disease (GVHD) characteristic of autoimmune disease, we used a cell-mediated lympholysis assay to study the autoreactivity of PBL from two patients after MHC-matched BMT. Our data indicate the induction of CD3+CD4-CD8+ autoreactive cytotoxic T lymphocytes (CTL) in the one patient with chronic GVHD and an important role for allo-non-MHC (minor histocompatibility) antigen-specific CD3+CD4+CD8- helper T cells in this induction. Experiments using HLA-DR gene-transfected mouse L cells as target cells and blocking assays with anti-HLA class I and class II antibodies provided evidence that autoreactive CTL recognized HLA-DR antigen on autologous cells. Analysis of antigen-specific T cell proliferative responses in these patients to examine the effect of self HLA-DR-specific CTL on the antigen presenting cell (APC)-T cell interaction suggested that donor bone marrow-derived self HLA-DR-specific CTL are responsible for the decreased antigen-presenting ability of the patient's APC. These results suggest a new interpretation of the induction mechanism of chronic GVHD and its associated immunosuppression after MHC-matched BMT based on diminished APC function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858527

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Emergent autoimmunity in graft-versus-host disease.

Authors:  Elizabeth Tivol; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

Review 2.  Reconstitution of self-tolerance after hematopoietic stem cell transplantation.

Authors:  Allan D Hess
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.